NCT06296212 is a Phase 3 clinical trial of TAD® 600 mg/4 mL powder and solvent for solution for injection in Pneumonia, sponsored by Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica.

Who is sponsoring NCT06296212?

NCT06296212 is sponsored by Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica.

What condition does NCT06296212 study?

NCT06296212 studies Pneumonia, Myocardial Injury.

Is NCT06296212 still recruiting?

NCT06296212 is currently recruiting now.

Last reviewed 2026-06-10 · How we verify

NCT06296212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.

Recruiting now Phase 3

What this trial tests

Phase 3 trial testing TAD® 600 mg/4 mL powder and solvent for solution for injection in Pneumonia in 178 participants. Currently enrolling.

Timeline

25 June 2024

30 September 2025

Quick facts

Lead sponsor	Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
Phase	Phase 3
Status	Recruiting now
Enrollment	178
Start date	25 June 2024
Estimated completion	30 September 2025

Drugs / interventions tested

TAD® 600 mg/4 mL powder and solvent for solution for injection — full drug profile →
Saline solution 0.9% of sodium chloride — full drug profile →

Conditions studied

Pneumonia — all drugs for Pneumonia →
Myocardial Injury — all drugs for Myocardial Injury →

Sponsor

Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica — full company profile →

Who can join

Eligibility, any sex, with Pneumonia or Myocardial Injury.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pneumonia

Currently open trials in the same condition.

NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
NCT07251465 — A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia · active not recruiting
NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
NCT06911658 — Infectious Complications After Esophagectomy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06296212 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06296212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing